October 29, 2026 |
1 min read |
In this episode of Denatured, you’ll hear from Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and APAC at Resolian. We discuss why Australia has become a magnet for early clinical development, and whether its speed, regulatory clarity and tax incentives are pushing it toward a more integrated biotech role.
> Listen on Spotify
> Listen on Apple Podcasts
> Listen on Amazon Music
> Watch on YouTube
In this episode of Denatured, you’ll listen to Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and APAC at Resolian. We look at why Australia attracts so much early clinical work, and whether its fast timelines, clear rules and tax breaks are turning it into a core player in the biotech industry
Host
Jennifer C. Smith-Parker, Director of Insights, BioSpace
Guests
Jerome Barley, Commercial Director, Avion Medical
Ryan Klein, Vice President, Business Development, US and APAC, Resolian
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Jennifer C. Smith-Parker is Director of Insights at BioSpace. She has been been immersed for 20 years in healthcare, first as a journalist and editor before pivoting to corporate, brand, and product communications. A skilled storyteller, she is adept at creating diverse content across platforms and crafting narratives that drive engagement, strengthen reputation, and deliver measurable growth. You can reach her at Jennifer.Smith-Parker@BioSpace.com.
The BioSpace Insights teams performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.
